Anemia. Anemia is assessed by measuring hemoglobin concentration in the blood. Among children 6- 59 months the three classifications of anemia are: “Mild” <11g/dl “Moderate” <9.5 g/dl “Severe” <8g/dl Some of the surveys used in the study give prevalence estimates for each classification of anemia while others only give the global prevalence (combined mild, moderate and severe prevalence). On the population level, the WHO rates the public health implications of anemia prevalence in four categories: “No public health problem”= prevalence < or = 4.9% “Mild public health problem”= prevalence 5.0-19.99% “Moderate public health problem”= prevalence 20.0-39.99% “Severe public health problem “= prevalence > or = 40.0%
Anemia. 1.16.4 The treatment of Hemophilia A or B through the delivery of Factor VIII, Factor IX or both; and
Anemia. Anemia is a common occurrence in PAH patients. If a patient has serum levels of hemoglobin < 10.5 g/dL at Screening, the patient will be allowed to re-screen following anemia treatment. Re-screening can occur no sooner than 30 days following initiation of anemia treatment. Patients with anemia who re-screen must repeat all Screening assessments at the re-screening. If the patient takes agents to treat anemia (including but not limited to supplemental iron, erythropoietin, or intravenous iron) the patient must remain on a stable dosage for at least 30 days prior to Day 1. If the patient receives intravenous iron therapy during Screening, the intravenous infusion must be performed at least 30 days prior to Day 1.
